Roche: diverse oncology data presented at ASCO.
(CercleFinance.com) - Roche said on Monday that a phase III study showed that Alecensa reduced the risk of disease progression or death by more than half, versus crizotinib, as first-line treatment in a specific type of lung cancer.
The medicine reduced the risk of disease worsening or death by 53% compared to crizotinib when given as initial treatment for people with ALK-positive advanced non-small cell lung cancer (NSCLC).
Alecensa also lowered the risk of tumours spreading or growth in the brain or the central nervous system.
The primary endpoint of the study, median progression-free survival reported by the investigators, was not yet reached.
Another study presented at ASCO meeting in Chicago showed that Roche's Perjeta-based regimen reduced the risk of cancer recurrence or death by 19% in people with HER2-positive early breast cancer compared to Herceptin and chemotherapy alone.
At three years, 94.1% of people treated with the Perjeta-based regimen did not have their a relapse in breast cancer, compared to 93.2% treated with Herceptin and chemotherapy.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The medicine reduced the risk of disease worsening or death by 53% compared to crizotinib when given as initial treatment for people with ALK-positive advanced non-small cell lung cancer (NSCLC).
Alecensa also lowered the risk of tumours spreading or growth in the brain or the central nervous system.
The primary endpoint of the study, median progression-free survival reported by the investigators, was not yet reached.
Another study presented at ASCO meeting in Chicago showed that Roche's Perjeta-based regimen reduced the risk of cancer recurrence or death by 19% in people with HER2-positive early breast cancer compared to Herceptin and chemotherapy alone.
At three years, 94.1% of people treated with the Perjeta-based regimen did not have their a relapse in breast cancer, compared to 93.2% treated with Herceptin and chemotherapy.
Copyright (c) 2017 CercleFinance.com. All rights reserved.